NEW YORK (GenomeWeb) – Meridian Bioscience marked its newly declared era of transparency earlier this month by holding the firm's first-ever conference call to recap its earnings. After one year at the helm, new CEO Jack Kenny used the call to announce a series of strategic business changes, including a plan to drive growth through directing profits to R&D projects rather than paying a locked-in dividend.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.